1 Year Outcome of Clinical Efficacy and Safety of Drug Coated Balloon Usage in Coronary Artery Disease in Thailand

Abstract

Background: Drug coated balloon is indicated as the treatment of in stent restenosis (ISR) and de novo lesion in coronary artery disease. The evidence of drug coated ballon (DCB) used for Thai patient in term of safety and efficacy is limited. Objectives: Our real-world cohort study was aimed to evaluate the paclitaxel coated balloon (Sequent please) for 1-year clinical efficacy and safety in Thai population. Methods: From June 2020 to January 2022, a total of 97 symptomatic patients with 100 procedures including de novo, bifurcation and in stent restenosis (ISR) were treated with DCB at Central Chest Institute of Thailand. The composite end point was major adverse cardiac events (MACE) which was a composite of cardiovascular death, target vessel related myocardial infarction (MI) and target lesion revascularization (TLR) at 12 months follow-up. Results: The majority of patients were presented with chronic stable angina (51%). The most common indication for the use of DEB was ISR (82%) followed by de novo lesion (17%), bifurcation lesions (1%). The mean DEB diameter of 2.88 ± 0.58 mm and average total length of 24.95 ± 8.80 mm. At 12 months follow-up, 4% of patients developed MACE in ISR subgroup only. MACE was mainly driven by TLR (4%) followed by target vessel related myocardial infarction (1%) .No cardiovascular death was occurred in study. Conclusion: In our cohort of Thai patients demonstrated that DCB was a safe and effective treatment modality with a low incidence of MACE observed at 12 months follow-up.